Maxim Phase II Clinical Trial Highlights Substantial Increase In Leukemia-FreeSurvival For Acute Myelogenous Leukemia Patients

diseases and cancer, the capacity of the patient's immune system to detect and destroy diseased cells is compromised. Maxamine Therapy combines the administration of Maxamine, which protects critical immune cells, with the administration of cytokines such as interferons or IL-2, which stimulate these immune cells.

Maxim scientists have shown that the suppressive effect of the phagocytes, a class of white blood cells, is an important mechanism that prevents the immune system from effectively fighting cancer. Phagocytes release free-radicals that induce T-cells and NK-cells, immune cells that are critical in the fight against cancer and infectious diseases, into programmed cell death or apoptosis. Cytokines, such as IL-2 and interferon-a and vaccines are potent stimulators of T-cells and NK-cells, yet they are often rendered ineffective as therapeutics due to phagocyte-derived free-radical induction of programmed cell death of the critical immune cells. Maxamine has been shown to clearly and effectively prevent the production and release of phagocyte-derived free radicals, thereby protecting T-cells and NK-cells and enhancing the immune stimulating capabilities of certain cytokines and other immunotherapies.

Complementing the AML results described above, Phase II clinical studies of Maxamine Therapy in advanced malignant melanoma have shown a more than doubling in survival outcomes and the maintenance of patient quality of life during treatment. Earlier-stage clinical studies have also suggested promise in renal cell carcinoma and hepatitis. "The growing body of human data in several cancers and viral infections is leading Maxim into a clinical development program that focuses Maxamine as an immuno-modulator that may be used broadly to improve cytokine therapy, cancer vaccines and other stimulators of the immune system," stated Larry Stambaugh, chairman and chief executive officer of Maxim.

Maxim Pharmaceuticals, Inc.

Maxim Pharmaceuticals

Contact: Amy Flood
415-677-4455 x211
Noonan/Russo Communications

Page: 1 2 3 4 5 6

Related medicine news :

1. Elan and Biogen Idec announce results from Phase III maintenance trial of Antegren
2. Phase II trial of anthrax vaccine to begin
3. NIAID Phase III HIV vaccine trial to determine correlates of protection will not proceed
4. MetaPhore Pharmaceuticals initiates Phase I clinical trial of enzyme mimetic compound for oncology
5. Maret Pharmaceuticals presents promising Phase I/II clinical MARstem™ results at international symposium on new drugs in cancer therapy
6. Penn researchers announce results of Phase I trial using combretastatin drug
7. Anti-cocaine vaccine produces antibodies and is shown to be safe in Phase 1 study conducted by Yale researcher
8. Results of NUVANCE (IL-4 receptor) in Phase I/II study in asthma patients featured at AAAAI Late-Breaker Abstract and Asthma Therapy Sessions
9. ILEX Oncology & LeukoSite report results from pivotal Phase II CAMPATH (R) trial; Results suggest new hope for refractory chronic lymphocytic leukemia
10. Abgenix Reports Positive Survival Data From A Phase II Trial Of ABX-CBL In Graft Versus Host Disease
11. Immunex Advances CD40 Ligand To Phase II Clinical Trial In People With Metastatic Kidney Cancer

Post Your Comments:

(Date:8/31/2018)... (PRWEB) , ... August 31, 2018 , ... ... will host an Open House on Wednesday, September 12 from 1:00-3:00 pm. ... in Grand Rapids, as well as tour the facility, meet our staff and ...
(Date:8/31/2018)... ... August 31, 2018 , ... The social impact documentary feature film on ... and NIH-funded researcher Luciana Lagana, aka Dr. Luciana, has been faring well ... Film International Film Festival, IndieFEST Film Awards, Shawna Shea Memorial Film Festival, and Top ...
(Date:8/31/2018)... ... ... Nitro Circus hosted the inaugural A Night to Live Like Roner event ... celebrate the life of Erik Roner, world-renowned skier, skydiver and a founding member of ... two small children, Oskar (8) and Kasper (4). A portion of the funds went ...
(Date:8/31/2018)... SCOTCH PLAINS, N.J. (PRWEB) , ... August 31, ... ... gastroenterologist, Dr. Joseph Savon of South Jersey Gastroenterology for another year. Dr. Savon ... has been one of the leaders in comprehensive care for all gastrointestinal diseases ...
(Date:8/31/2018)... , ... August 31, 2018 , ... ... to announce the promotion of Nitin Arneja to Chief Information Officer. Arneja previously ... the efforts to develop technology solutions that protect, optimize, scale, and innovate the ...
Breaking Medicine News(10 mins):
(Date:9/12/2018)... ... September 12, 2018 , ... Lifetime Wellness , a leading provider ... launch of a new online store to offer exclusive aromatherapy products to a wider ... thrilled to open our online store to offer our custom aromatherapy to not only ...
(Date:9/7/2018)... ... 06, 2018 , ... This year, the California Society of Plastic Surgeons (CSPS) ... IDEAL IMPLANT® - Seven-Year Clinical Trial Results at the 68th CSPS Annual Meeting. ... ASPS (American Society of Plastic Surgeons) meeting in Chicago this fall. , “I am ...
(Date:9/3/2018)... , ... September 03, 2018 , ... ... number of residents with more than 1,200 residents and 200 fellows for the ... Carolina twenty-third-largest in the nation. Charleston area institutions such as McLeod Health, MUSC ...
Breaking Medicine Technology:
Cached News: